Sandoz HACk Competition for Healthcare Access and a Prize of $20,000
Applicant criteria
- Both
Opportunity criteria
Opportunity description
Do you have a digital solution to a local healthcare access challenge?
Sandoz invites inspirational ideas that use digital technology with the potential to complement established approaches to healthcare access to participate in the Sandoz HACk global competition. Universal access to healthcare remains the single largest unmet medical need. Two billion people don’t have access to the medicines they need, and four hundred million lack access to essential health services. Simply submit your idea on how digital technology can improve access to medicines in your community.
To participate, you must fulfill the following:
[1] The healthcare access challenge you are addressing
[2] Your proposed solution to the access challenge
[3] Solving the access challenge with a digital solution
[4] Applying your idea beyond your country
[5] Seeking synergies with areas of expertise within Sandoz
[6] Your entry must be submitted in English
[7] You must be able and available to travel and enter the USA in March 2019
Prize:
The Competition winner will be awarded with one cash prize of €20,000 which shall be entirely used to implement their idea within two years. Sandoz will work with shortlisted entrants to incubate and enhance their ideas, in order to arrive at practical, scalable solutions that help improve people’s lives in communities around the world. Those with the best ideas will travel to South by Southwest (Austin, Texas) in March 2019, to participate in a five-day Accelerator event, to evolve their ideas into an actionable business plan.
About Sandoz:
Sandoz is a global leader in generic and biosimilar medicines, committed to playing a leading role in driving access to medicine worldwide. It discovers new ways to improve and extend people’s lives and pioneer novel approaches to help people around the world access high-quality medicine. It is led by a diverse team with extensive experience in the generic pharmaceutical and biopharmaceutical industry.